Table 9.12a
Adjusted Patient Survival, Deceased Donor Liver Transplants
Survival at 3 Months, 1 Year, 3 Years, and 5 Years

	3 Months			1 Year			3 Years			5 Years		
	(Tx 2003 - 2004)			(Tx 2003 - 2004)			(Tx 2001 - 2004)			(Tx 1999 - 2004)		
	N	%	Std. Err.	N	%	Std. Err.	N	%	Std. Err.	N	%	Std. Err.
Total												
All	9,613	93.2%	0.3%	9,613	87.0%	0.3%	17,892	79.0%	0.4%	25,762	73.3%	0.4%
Age at Tx												
<1 Year	238	93.8%	1.6%	238	92.2%	1.8%	455	86.2%	1.8%	684	80.3%	1.8%
1-5 Years	277	90.7%	1.8%	277	86.5%	2.1%	564	82.4%	1.8%	814	81.0%	1.6%
6-10 Years	133	92.6%	2.3%	133	91.1%	2.5%	231	86.3%	2.6%	366	87.8%	1.8%
11-17 Years	226	95.6%	1.4%	226	93.0%	1.7%	484	87.1%	1.8%	686	81.9%	1.9%
18-34 Years	500	88.7%	1.4%	500	84.9%	1.6%	940	81.4%	1.4%	1,376	76.6%	1.4%
35-49 Years	2,581	93.9%	0.5%	2,581	87.9%	0.6%	5,196	80.3%	0.6%	8,055	74.8%	0.6%
50-64 Years	4,884	93.5%	0.4%	4,884	86.8%	0.5%	8,783	77.6%	0.5%	12,087	72.0%	0.5%
65+ Years	902	90.3%	1.0%	902	81.1%	1.3%	1,512	71.0%	1.4%	2,107	62.5%	1.4%
Recipient Ethnicity/Race												
White	6,978	93.4%	0.3%	6,978	87.1%	0.4%	13,049	79.2%	0.4%	18,983	73.6%	0.4%
African American	907	92.3%	0.9%	907	84.0%	1.2%	1,638	73.5%	1.3%	2,310	64.8%	1.3%
Hispanic/Latino	1,193	93.3%	0.7%	1,193	87.6%	1.0%	2,248	81.1%	0.9%	3,169	76.0%	1.0%
Asian	453	93.0%	1.2%	453	88.9%	1.5%	831	80.9%	1.6%	1,115	77.3%	1.6%
Other/Multi-race	82	94.8%	2.5%	82	90.8%	3.3%	126	75.5%	5.0%	185	74.8%	3.7%
Recipient Gender												
Female	3,330	92.4%	0.5%	3,330	86.4%	0.6%	6,214	79.7%	0.6%	9,205	73.3%	0.6%
Male	6,283	93.7%	0.3%	6,283	87.2%	0.4%	11,678	78.6%	0.4%	16,557	73.2%	0.4%

Source: OPTN/SRTR Data as of May 1, 2006.

Notes:

(+) = Values not determined due to insufficient follow-up. (-) = Values not determined since there were no transplants in the category.

Cohorts are transplants performed during the years listed at the top of the table.

Patient survival follows patients from first transplant of this type until death. Counts for patient and graft survival are different because a patient may have more than one transplant for a type of organ.

Center volume = Center's yearly transplants performed during the base period, based on liver transplants.

Multi-organ transplants are excluded.

Survival rates are adjusted to the characteristics of the 3 month and 1 year cohort. See Technical Notes for details.

Table 9.12a (Continued)
Adjusted Patient Survival, Deceased Donor Liver Transplants
Survival at 3 Months, 1 Year, 3 Years, and 5 Years

	3 Months			1 Year			3 Years			5 Years		
	(Tx 2003 - 2004)			(Tx 2003 - 2004)			(Tx 2001 - 2004)			(Tx 1999 - 2004)		
	N	%	Std. Err.	N	%	Std. Err.	N	%	Std. Err.	N	%	Std. Err.
Total												
All	9,613	93.2%	0.3%	9,613	87.0%	0.3%	17,892	79.0%	0.4%	25,762	73.3%	0.4%
Primary Diagnosis												
Non-Cholestatic Cirrhosis	5,937	93.8%	0.3%	5,937	86.9%	0.5%	11,393	78.5%	0.5%	16,727	71.8%	0.5%
Cholestatic Liver Disease/Cirrhosis	856	93.6%	0.8%	856	89.7%	1.0%	1,675	83.7%	1.0%	2,513	81.0%	0.9%
Acute Hepatic Necrosis	747	89.6%	1.1%	747	84.0%	1.4%	1,379	74.5%	1.4%	2,085	70.2%	1.2%
Biliary Atresia	313	92.2%	2.1%	313	90.8%	2.3%	598	85.8%	2.2%	892	85.4%	1.7%
Metabolic Diseases	307	92.5%	1.6%	307	87.6%	2.0%	597	82.7%	1.9%	864	79.6%	1.7%
Malignant Neoplasms	759	93.1%	0.9%	759	85.9%	1.3%	1,188	74.8%	1.6%	1,350	64.1%	2.3%
Other	694	92.6%	1.0%	694	86.4%	1.3%	1,062	81.1%	1.4%	1,331	74.7%	1.6%

Source: OPTN/SRTR Data as of May 1, 2006.
Notes:
(+) = Values not determined due to insufficient follow-up. (-) = Values not determined since there were no transplants in the category.
Cohorts are transplants performed during the years listed at the top of the table.
Patient survival follows patients from first transplant of this type until death. Counts for patient and graft survival are different because a patient may have more than one transplant for a type of organ.
Center volume = Center's yearly transplants performed during the base period, based on liver transplants.
Multi-organ transplants are excluded.
Survival rates are adjusted to the characteristics of the 3 month and 1 year cohort. See Technical Notes for details.